Stephen K. Doberstein, SVP & Chief Scientific Officer at NEKTAR THERAPEUTICS (NKTR), sold 160,000 shares at $91.69 ($14.9M) on 2018-04-06, disclosed to the SEC on 2018-04-09.
Open-market sale of $14.9M NKTR by SVP & Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $91.69 | 110,500 | $10.1M | 68.0% |
| 2 | $96.13 | 49,500 | $4.8M | 32.0% |
| Total | $93.06 avg | 160,000 | $14.9M | 100% |
| Filing → |
| NKTR | SELL | 2019-05-17 | $217K | — | Filing → |
| NKTR | SELL | 2019-02-21 | $281K | — | Filing → |
| NKTR | SELL | 2018-11-19 | $173K | — | Filing → |